Loading...
•
Jun 30, 2021
Ironwood Pharmaceuticals Q2 2021 Earnings Report
Reported strong second-quarter results and raised full-year guidance.
Key Takeaways
Ironwood Pharmaceuticals reported a strong second quarter in 2021, with U.S. LINZESS net sales increasing by 18% year-over-year to $259 million and total revenue increasing by 16% year-over-year to $104 million. The company's GAAP net income was $391 million, which included a $338 million non-recurring income tax benefit. Ironwood ended the quarter with $493 million in cash and cash equivalents and raised its full-year 2021 financial guidance.
U.S. LINZESS net sales of $259 million, an increase of 18% year-over-year
Total revenue of $104 million, an increase of 16% year-over-year, driven primarily by U.S. LINZESS collaboration revenue of $100 million
GAAP net income of $391 million, includes a $338 million non-recurring income tax benefit related to the release of the valuation allowance against the majority of the company’s deferred tax assets
Adjusted EBITDA of $65 million; ended Q2 2021 with $493 million in cash and cash equivalents
Forward Guidance
Ironwood is raising its 2021 financial guidance due to the growth in U.S. LINZESS prescription demand.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...